Abstract: The present invention provides an external preparation which can improve a skin permeability of a hydrophilic medicine such as NSAID so that the medicine can act directly on a diseased area without passing through gastrointestinal tract or mucosa. The S/O type external preparation external preparation excellent in percutaneous absorbability of the present invention comprises a medicine-containing complex dissolved or dispersed in an oil phase, wherein the complex contains a hydrophilic medicine covered with a surfactant and is in a form of a solid.

Abstract: The object of the present invention is to provide a drug having therapeutic effect on muscular dystrophy without lowering renal function. The therapeutic drug for muscular dystrophy of the present invention comprises a caldecrin or a caldecrin gene.

Abstract: The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-R(SEQ ID No. 1) (in the formula, H means hydrogen, A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine residue, A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine, leucine, or tyrosine residue, A3 is lysine, valine, aspartic acid, arginine, alanine, or tryptophan residue, A4 is alanine, tryptophan, or glycine residue, A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue, R is OH derived from carboxyl group or NH2 derived from acid amide group). The above peptide has an affinity to gp120 of the HIV envelope protein and is superior in stability.

Abstract: The present invention provides a pharmaceutical preparation that significantly reduces leakage of a low-molecule medicine in a strong acidic environment, while allowing release of the low-molecule medicine in the enteric canal or the like which is in a weak acidic to neutral environment. The S/O type pharmaceutical preparation of the present invention is characterized in comprising a medicine-containing complex dissolved or dispersed in an oil phase, wherein the complex contains a mixture and a surfactant, the mixture is covered by the surfactant, and the mixture contains a hydrophilic low molecule medicine, and a hydrophilic medicine-leakage-suppressive protein and/or a medicine-leakage-suppressive polysaccharide.